Investor Center

Press Releases

Press Releases

September 30, 2020
CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its public offering of 5,000,000 shares of common stock at a public offering price of
July 30, 2020
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following August investor conferences: William Blair Biotech Focus
June 15, 2020
– MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 15, 2020-- Magenta Therapeutics (Nasdaq: MGTA) and Beam
Displaying 1 - 10 of 16